Gaboxadol - Healx Limited
Alternative Names: HLX-0206Latest Information Update: 02 Apr 2024
At a glance
- Originator Healx
- Class Antidepressants; Antiepileptic drugs; Isoxazoles; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Fragile X syndrome
Most Recent Events
- 19 Jan 2024 Healx initiates a phase II trial in Fragile X syndrome (In adults) in USA (PO) (NCT06334419)
- 27 Jul 2022 Gaboxadol - Healx Limited is available for licensing as of 27 Jul 2022. https://healx.io/partnerships/ (Healx pipeline, July 2022)
- 25 May 2022 Phase-II clinical trials in Fragile X syndrome (Combination therapy, In adolescents, In adults) in USA (PO) (NCT04823052)